The Medical Letter on Drugs and Therapeutics
Bedaquiline (Sirturo) for Multidrug-Resistant Tuberculosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Bedaquiline (Sirturo) for Multidrug-Resistant Tuberculosis
Bedaquiline (bed ak' wi leen; Sirturo – Janssen), a diarylquinoline antimycobacterial, has been given accelerated approval by the FDA as an orphan drug for use in addition to other drugs for treatment of adults with multidrug-resistant...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Bedaquiline (Sirturo) for Multidrug-Resistant Tuberculosis
Article code: 1423b
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.